Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/06/2020 08/07/2020 08/10/2020 08/11/2020 08/12/2020 Date
1550(c) 1555.2(c) 1553.2(c) 1576(c) 1611.6 Last
4 691 863 4 168 560 3 771 920 4 860 696 6 122 159 Volume
-1.47% +0.34% -0.13% +1.47% +2.26% Change
More quotes
Financials
Sales 2020 35 040 M 45 714 M 45 714 M
Net income 2020 4 781 M 6 237 M 6 237 M
Net Debt 2020 22 747 M 29 676 M 29 676 M
P/E ratio 2020 15,3x
Yield 2020 5,08%
Sales 2021 36 136 M 47 144 M 47 144 M
Net income 2021 4 330 M 5 648 M 5 648 M
Net Debt 2021 21 140 M 27 580 M 27 580 M
P/E ratio 2021 18,0x
Yield 2021 5,08%
Capitalization 78 435 M 103 B 102 B
EV / Sales 2020 2,89x
EV / Sales 2021 2,76x
Nbr of Employees 99 437
Free-Float 91,3%
More Financials
Company
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%); - OTC and parapharmaceutical medicine (26.7%); - vaccines (21.2%); - other (0.1%). Net sales are distributed geographically as... 
More about the company
Surperformance© ratings of GlaxoSmithKline plc
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PLC
02:38aGLAXOSMITHKLINE : UBS maintains a Buy rating
MD
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
RE
08/11Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
RE
08/10GLAXOSMITHKLINE : CureVac Sets IPO at 13.3 Million Shares; Sees Pricing at $14-$..
DJ
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
RE
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
RE
08/10Biotech company CureVac aims to raise up to $245 mln in U.S. IPO
RE
08/07GLAXOSMITHKLINE : FDA approves GSK's BLENREP for the treatment of patients with ..
AQ
08/06GLAXOSMITHKLINE : FDA approves GSK's BLENREP (belantamab mafodotin-blmf) for the..
AQ
08/05GLAXOSMITHKLINE : U.S. FDA approves GlaxoSmithKline's blood cancer drug
RE
08/05GLAXOSMITHKLINE : FDA approves GSK's BLENREP (belantamab mafodotin-blmf) for the..
PU
08/03FOCUS : Next big COVID-19 treatment may be manufactured antibodies
RE
08/03Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
DJ
08/03GlaxoSmithKline and Sanofi to Supply EU With 300 Million Covid-19 Doses
DJ
08/01WHAT'S NEWS : World-Wide -- WSJ
DJ
More news
News in other languages on GLAXOSMITHKLINE PLC
02:38aGLAXOSMITHKLINE : UBS maintient sa recommandation à l'achat
02:38aGLAXOSMITHKLINE : UBS maintains a Buy rating
02:38aUBS senkt Ziel für GlaxoSmithKline auf 1800 Pence - 'Buy'
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
08/11Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 1 867,21 GBX
Last Close Price 1 576,00 GBX
Spread / Highest target 42,1%
Spread / Average Target 18,5%
Spread / Lowest Target -2,47%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-11.41%102 598
JOHNSON & JOHNSON1.48%386 946
ROCHE HOLDING AG-0.35%292 091
PFIZER, INC.-3.55%209 994
MERCK & CO., INC.-11.04%204 641
NOVARTIS AG-17.07%183 277